Impact of BNT162b2 Vaccination and Isolation on SARS-CoV-2 Transmission in Israeli Households: An Observational Study.


Journal

American journal of epidemiology
ISSN: 1476-6256
Titre abrégé: Am J Epidemiol
Pays: United States
ID NLM: 7910653

Informations de publication

Date de publication:
27 06 2022
Historique:
received: 02 09 2021
revised: 02 02 2022
accepted: 01 03 2022
pubmed: 4 3 2022
medline: 6 7 2022
entrez: 3 3 2022
Statut: ppublish

Résumé

Several studies have characterized the effectiveness of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. However, estimates of their impact on transmissibility remain limited. Here, we evaluated the impact of isolation and vaccination (7 days after the second dose) on SARS-CoV-2 transmission within Israeli households. From December 2020 to April 2021, confirmed cases were identified among health-care workers of the Sheba Medical Centre and their family members. Recruited households were followed up with repeated PCR for at least 10 days after case confirmation. Data were analyzed using a data augmentation Bayesian framework. A total of 210 households with 215 index cases were enrolled; 269 out of 667 (40%) susceptible household contacts developed a SARS-CoV-2 infection. Of those, 170 (63%) developed symptoms. Compared with unvaccinated and unisolated adult/teenager (aged >12 years) contacts, vaccination reduced the risk of infection among unisolated adult/teenager contacts (relative risk (RR) = 0.21, 95% credible interval (CrI): 0.08, 0.44), and isolation reduced the risk of infection among unvaccinated adult/teenager (RR = 0.12, 95% CrI: 0.06, 0.21) and child contacts (RR = 0.17, 95% CrI: 0.08, 0.32). Infectivity was reduced in vaccinated cases (RR = 0.25, 95% CrI: 0.06, 0.77). Within households, vaccination reduces both the risk of infection and of transmission if infected. When contacts were unvaccinated, isolation also led to important reductions in the risk of transmission.

Identifiants

pubmed: 35238329
pii: 6541606
doi: 10.1093/aje/kwac042
pmc: PMC8903452
doi:

Substances chimiques

BNT162 Vaccine N38TVC63NU

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1224-1234

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health.

Références

BMJ Open. 2020 Aug 16;10(8):e039652
pubmed: 32801208
Am J Epidemiol. 2022 Mar 30;:
pubmed: 35355048
Lancet Infect Dis. 2021 May;21(5):617-628
pubmed: 33476567
Clin Infect Dis. 2021 Aug 2;73(3):e754-e764
pubmed: 33560412
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Cell Rep Med. 2021 May 18;2(5):100264
pubmed: 33899031
JAMA Pediatr. 2021 Feb 1;175(2):143-156
pubmed: 32975552
Elife. 2021 Feb 05;10:
pubmed: 33543709
N Engl J Med. 2021 Oct 28;385(18):1718-1720
pubmed: 34496200
Lancet Infect Dis. 2020 Oct;20(10):1141-1150
pubmed: 32562601
Euro Surveill. 2021 May;26(21):
pubmed: 34047271
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Stat Med. 2004 Nov 30;23(22):3469-87
pubmed: 15505892
N Engl J Med. 2021 Aug 19;385(8):759-760
pubmed: 34161702
Nat Med. 2021 Aug;27(8):1370-1378
pubmed: 34108716
Med (N Y). 2021 Aug 13;2(8):979-992.e8
pubmed: 34223401
Lancet. 2020 Mar 14;395(10227):e47
pubmed: 32113505
Lancet Infect Dis. 2020 Aug;20(8):911-919
pubmed: 32353347
Science. 2022 Mar 11;375(6585):1151-1154
pubmed: 35084937
Lancet Reg Health Eur. 2021 Aug;7:100150
pubmed: 34250518
Lancet Microbe. 2021 Jan;2(1):e13-e22
pubmed: 33521734
Nat Hum Behav. 2021 Jul;5(7):947-953
pubmed: 33972767
Clin Infect Dis. 2022 Jan 7;74(1):59-65
pubmed: 33704435
Lancet Public Health. 2020 Jul;5(7):e375-e385
pubmed: 32502389
N Engl J Med. 2021 Dec 23;385(26):2489-2491
pubmed: 34941024
JAMA Netw Open. 2020 Dec 1;3(12):e2031756
pubmed: 33315116
Nat Commun. 2022 Mar 4;13(1):1162
pubmed: 35246536
J Infect. 2020 Dec;81(6):979-997
pubmed: 32858069
Clin Immunol. 2021 Jan;222:108634
pubmed: 33217545
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
Nature. 2021 May;593(7858):266-269
pubmed: 33767447
Euro Surveill. 2021 Aug;26(31):
pubmed: 34355689

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH